Skip to content

Safety and Feasibility of the ELIOS System in POAG Patients

A Prospective, Multicenter, Clinical Trial Designed to Evaluate the Safety and Feasibility of the ELIOS System to Reduce Intraocular Pressure in Patients With Primary Open-Angle Glaucoma as a Standalone Procedure

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05999006
Enrollment
22
Registered
2023-08-21
Start date
2023-10-18
Completion date
2026-04-28
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Primary Open Angle

Brief summary

Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG)

Interventions

Treatment with the ELIOS System

Sponsors

Elios Vision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of mild to moderate POAG * Medicated IOP of \<=24 mmHg * Shaffer angle grade of III or IV * CD ratio \<=0.8 * At least 45 years old

Exclusion criteria

* Closed-angle and secondary glaucomas * Prior incisional glaucoma surgery, intraocular surgery, or corneal surgery * Cannot undergo medication washout in the study eye * Diagnosis of degenerative visual disorders Non-study eye with BCVA worse than 20/80 Known corticosteroid responder Pregnant or nursing women; or women of childbearing potential not using medically acceptable birth control

Design outcomes

Primary

MeasureTime frameDescription
Proportion of subjects who achieve a decrease in mean diurnal IOP (DIOP) from baseline of at least 20% on the same or fewer medications12 MonthsProportion of subjects who achieve a decrease in mean diurnal IOP (DIOP) from baseline of at least 20% on the same or fewer medications
Mean Change in DIOP from baseline on the same or fewer medications12 MonthsMean Change in DIOP from baseline on the same or fewer medications

Countries

United States

Contacts

STUDY_DIRECTORIqbal (Ike) Ahmed, MD

Prism Eye Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026